Presentations & Publications

Listeria monocytogenes (Lm)-LLO Immunotherapies Reduce the Immunosuppressive Activity of Myeloid-derived Suppressor Cells and Regulatory T Cells in the Tumor Microenvironment

UPLOADED:

December 11, 2013

Listeria monocytogenes (Lm)-LLO Immunotherapies Reduce the Immunosuppressive Activity of Myeloid-derived Suppressor Cells and Regulatory T Cells in the Tumor Microenvironment

UPLOADED:

November 1, 2013

ADXS11-001 LM-LLO Immunotherapy Targeting HPV-E7: Preliminary Safety and Survival Data From a Phase 2 Study in Indian Women With Recurrent/Refractory Cervical Cancer

UPLOADED:

November 1, 2013

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy

UPLOADED:

August 29, 2013

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy

UPLOADED:

August 29, 2013

Listeria monocytogenes-Derived Listeriolysin O Has Pathogen Associated Molecular Pattern-Like Properties Independent of Its Hemolytic Ability

UPLOADED:

January 4, 2013

Listeria monocytogenes-Derived Listeriolysin O Has Pathogen Associated Molecular Pattern-Like Properties Independent of Its Hemolytic Ability

UPLOADED:

January 4, 2013

Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.

UPLOADED:

December 6, 2012

Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer

UPLOADED:

November 1, 2012

Lm-LLO-Based Immunotherapies and HPV-Associated Disease

UPLOADED:

October 1, 2012

STAY TUNED

Mailing List

Sign up for email alerts for Press Releases and Advaxis' breaking news.

SOCIAL

Follow Us

Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.